Mainstay Medical
- Industry
- Medical Devices
- Founded Year
- 2008
- Headquarters
- San Diego, California, USA
- Employee Count
- 181
Key People
- Jason Hannon - Chief Executive Officer
- David Brownlee - Vice President, Marketing
- Chris Collins - Vice President of Human Resources
- Bryan Cornwall - Senior Vice President, Research and Clinical
- Ben Goss - Vice President, Research
- Chris Linden - Vice President of Technology
- Matt Onaitis - Chief Financial Officer
- Liesl Oldstone - Vice President of Reimbursement and Market Access
- Corey Swift - Vice President of Sales, Australia
- Elias Tu - Vice President of Sales, United States
- Andrew Tochterman - Chief Commercial Officer
- Holger Witkowski - Managing Director, Europe
- Jim Youssef, MD - Senior Vice President of Medical and Scientific Affairs
Assessment
- Team
-
Aspect: Multiple successful MedTech entrepreneurs
Summary: The leadership team comprises experienced professionals with a strong background in medical devices.
Mainstay Medical's leadership includes individuals with extensive experience in the medical device industry, positioning the company well for success.
- Clinical Need
-
Aspect: Very Strong
Summary: ReActiv8 addresses a significant unmet need in treating mechanical chronic low back pain.
Chronic low back pain is a prevalent condition with limited effective treatments, making ReActiv8's restorative approach highly valuable.
- Competition
-
Aspect: Somewhat crowded
Summary: The market includes established players like Nevro and Boston Scientific.
While ReActiv8 offers a unique mechanism, it competes with other neurostimulation devices and alternative treatments for chronic back pain.
- Technical Challenge
-
Aspect: Moderate
Summary: Developing and commercializing implantable neurostimulation devices involves moderate technical challenges.
The technology requires precise engineering and clinical validation but is feasible with the company's expertise.
- Patent
-
Aspect: Very Strong
Summary: Mainstay Medical holds a dominant intellectual property portfolio for ReActiv8.
The company's robust patent portfolio provides a competitive advantage and protects its innovative technology.
- Financing
-
Aspect: Well-funded
Summary: The company secured $125 million in equity financing in 2024.
The substantial funding supports commercial growth and clinical studies, indicating strong financial backing.
- Regulatory
-
Aspect: 510k/PMA + Reimbursement
Summary: ReActiv8 has FDA approval and favorable reimbursement coverage.
Achieving regulatory approval and reimbursement positions the product well for market adoption.
Opportunity Rollup
- Odds of Success
- 3.55
- Peak Market Share
- 4.65
- Segment CAGR
- 4.9%
- Market Segment
- Neurology Devices
- Market Sub Segment
- Neurostimulation Devices
| Year Post Launch | Market Penetration (%) |
|---|---|
| 1 | 0.23 |
| 2 | 0.70 |
| 3 | 1.63 |
| 4 | 3.25 |
| 5 | 4.65 |
Key Takeaway
Mainstay Medical's ReActiv8 addresses a significant unmet need in chronic low back pain treatment, supported by strong leadership, robust patents, and substantial funding, positioning the company well in a competitive market.